デフォルト表紙
市場調査レポート
商品コード
1293777

ヘッジホッグ経路阻害剤市場:ジェネリック医薬品名(Glasdegib、Sonidegib、Vismodegib)、用量(カプセル、注射)、流通チャネル、がん適応症、エンドユーザー別-2023-2030年世界予測

Hedgehog Pathway Inhibitors Market by Generic Drug Name (Glasdegib, Sonidegib, Vismodegib), Dosage (Capsule, Injection), Distribution Channel, Cancer Indication, End-Users - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 183 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.66円
ヘッジホッグ経路阻害剤市場:ジェネリック医薬品名(Glasdegib、Sonidegib、Vismodegib)、用量(カプセル、注射)、流通チャネル、がん適応症、エンドユーザー別-2023-2030年世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヘッジホッグ経路阻害剤の世界市場は、2023年に13億2,709万米ドル、CAGR16.32%と大きく成長し、2030年には38億9,571万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のヘッジホッグ経路阻害剤市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.ヘッジホッグ経路阻害剤の世界市場規模および予測は?

2.予測期間中、世界のヘッジホッグ経路阻害剤市場を形成するCOVID-19の阻害要因と影響は?

3.ヘッジホッグ経路阻害剤の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は?

4.ヘッジホッグ経路阻害剤の世界市場における競争戦略は?

5.ヘッジホッグ経路阻害剤の世界市場における技術動向と規制の枠組みは?

6.ヘッジホッグ経路阻害剤の世界市場における主要ベンダーの市場シェアは?

7.ヘッジホッグ経路阻害剤の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • AMLとBCCについての意識を高めるためのプログラムの数が増加
      • 低侵襲手術の需要の高まり
      • 世界中でガンが大幅に蔓延
    • 抑制要因
      • 一次抵抗別採用の欠如
    • 機会
      • ヘッジホッグ経路阻害剤の承認数が増加
      • 継続的な研究開発活動
    • 課題
      • 有効性と安全性の問題への懸念
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 ヘッジホッグ経路阻害剤市場ジェネリック医薬品名別

  • グラスデジブ
  • ソニデギブ
  • ビスモデギブ

第7章 ヘッジホッグ経路阻害剤市場用量別

  • カプセル
  • 注入

第8章 ヘッジホッグ経路阻害剤市場:流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 ヘッジホッグ経路阻害剤市場がんの適応別

  • 膵臓
  • 前立腺

第10章 ヘッジホッグ経路阻害剤市場:エンドユーザー別

  • ホームケア
  • 病院
  • 専門クリニック

第11章 南北アメリカのヘッジホッグ経路阻害剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域のヘッジホッグ経路阻害剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのヘッジホッグ経路阻害剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第15章 掲載企業一覧

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HEDGEHOG PATHWAY INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2022 VS 2030 (%)
  • FIGURE 5. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2022 VS 2030 (%)
  • FIGURE 6. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2022 VS 2030 (%)
  • FIGURE 8. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
  • FIGURE 9. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. HEDGEHOG PATHWAY INHIBITORS MARKET DYNAMICS
  • FIGURE 11. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. HEDGEHOG PATHWAY INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. HEDGEHOG PATHWAY INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HEDGEHOG PATHWAY INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 5. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GLASDEGIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY SONIDEGIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY VISMODEGIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 9. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY BRAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 236. HEDGEHOG PATHWAY INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. HEDGEHOG PATHWAY INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. HEDGEHOG PATHWAY INHIBITORS MARKET LICENSE & PRICING
目次
Product Code: MRR-3E376243AB90

The Global Hedgehog Pathway Inhibitors Market is forecasted to grow significantly, with a projected USD 1,327.09 million in 2023 at a CAGR of 16.32% and expected to reach a staggering USD 3,895.71 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Hedgehog Pathway Inhibitors Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Hedgehog Pathway Inhibitors Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Generic Drug Name, market is studied across Glasdegib, Sonidegib, and Vismodegib. The Vismodegib commanded largest market share of 43.23% in 2022, followed by Sonidegib.

Based on Dosage, market is studied across Capsule and Injection. The Injection commanded largest market share of 86.32% in 2022, followed by Capsule.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy commanded largest market share of 72.12% in 2022, followed by Retail Pharmacy.

Based on Cancer Indication, market is studied across Blood, Brain, Breast, Lung, Pancreas, Prostate, and Skin. The Skin commanded largest market share of 21.23% in 2022, followed by Blood.

Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics. The Hospitals commanded largest market share of 49.23% in 2022, followed by Specialty Clinics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 41.54% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Hedgehog Pathway Inhibitors Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Hedgehog Pathway Inhibitors Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hedgehog Pathway Inhibitors Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hedgehog Pathway Inhibitors Market?

4. What is the competitive strategic window for opportunities in the Global Hedgehog Pathway Inhibitors Market?

5. What are the technology trends and regulatory frameworks in the Global Hedgehog Pathway Inhibitors Market?

6. What is the market share of the leading vendors in the Global Hedgehog Pathway Inhibitors Market?

7. What modes and strategic moves are considered suitable for entering the Global Hedgehog Pathway Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hedgehog Pathway Inhibitors Market, by Generic Drug Name, 2022 vs 2030
  • 4.3. Hedgehog Pathway Inhibitors Market, by Dosage, 2022 vs 2030
  • 4.4. Hedgehog Pathway Inhibitors Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Hedgehog Pathway Inhibitors Market, by Cancer Indication, 2022 vs 2030
  • 4.6. Hedgehog Pathway Inhibitors Market, by End-Users, 2022 vs 2030
  • 4.7. Hedgehog Pathway Inhibitors Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of programs to create awareness about AML and BCC
      • 5.1.1.2. Growing demand of minimally invasive surgeries
      • 5.1.1.3. Significant prevalence of cancer across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of adoption due to primary resistance
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in approvals for hedgehog pathway inhibitors
      • 5.1.3.2. Ongoing research and development activities
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding efficacy and safety issues
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Hedgehog Pathway Inhibitors Market, by Generic Drug Name

  • 6.1. Introduction
  • 6.2. Glasdegib
  • 6.3. Sonidegib
  • 6.4. Vismodegib

7. Hedgehog Pathway Inhibitors Market, by Dosage

  • 7.1. Introduction
  • 7.2. Capsule
  • 7.3. Injection

8. Hedgehog Pathway Inhibitors Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Hedgehog Pathway Inhibitors Market, by Cancer Indication

  • 9.1. Introduction
  • 9.2. Blood
  • 9.3. Brain
  • 9.4. Breast
  • 9.5. Lung
  • 9.6. Pancreas
  • 9.7. Prostate
  • 9.8. Skin

10. Hedgehog Pathway Inhibitors Market, by End-Users

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Hedgehog Pathway Inhibitors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Hedgehog Pathway Inhibitors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Hedgehog Pathway Inhibitors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

1. BridgeBio Inc.

2. Eli Lilly and Company

3. F. Hoffmann La Roche Ltd.

4. Impact Therapeutics Inc.

5. Kintor Pharmaceutical Limited

6. Max Biopharma Inc.

7. Merck KGaA

8. Novartis AG

9. Pellepharm, Inc.

10. Pfizer Inc.

11. Sanofi S.A.

12. Sun Pharmaceutical Industries Ltd.